Healthcare

Renalytix plc Financial Performance for First Quarter of Fiscal Year...

Highlights:,Continued test ordering growth at a prominent New York-based physician group practice.,Cash burn reduced to an approximate monthly rate by...

SkinBioTherapeutics and Croda Finalize Partnership for SkinBiotix Co...

Highlights:,Commercial Partnership Secured:,SkinBioTherapeutics to receive royalties on global sales of Croda’s products utilizing SkinBiotix technolo...

GSK’s linerixibat successfully meets primary study endpoint

Highlights:,GSK's linerixibat candidate shows positive results in Phase III trial for cholestatic pruritus in primary biliary cholangitis (PBC).,The t...

LungLife AI Advances Commercialisation of Lung Cancer Diagnostic Tes...

Highlights:,Positive Reception for LungLB:,Doctors in the Early Access Program report encouraging feedback, with orders placed and integration evaluat...

Revolutionizing Medicine: The Expanding Frontier of mRNA Technology

Highlights:,mRNA’s Broad Potential:,Beyond COVID-19 vaccines, mRNA technology is revolutionizing treatments for cancer and infectious diseases.,BioNTe...

SkinBioTherapeutics plc (SBTX:AIM) Finalizes Commercial Agreement wi...

Highlights:,Commercial terms finalized with Croda, based on successful results from additional clinical studies.,SkinBioTherapeutics expects to be cas...

Spire Healthcare Completes Execution of Share Buyback Program

Highlights:,Spire Healthcare Group PLC has initiated a share buyback program, repurchasing 50,000 shares.,The share buyback reduces the total number o...

Halma plc (HLMA: LSE) Expands Healthcare Sector with Acquisition of...

Highlights:,Halma acquires Lamidey Noury Medical for €50m (£42m) to enhance its portfolio of advanced medical technologies.,Lamidey Noury, based in Fr...

Pharma Stocks Sink After Trump's Controversial Health Secretary Appo...

Highlights:,Pharma Market Shock:,Appointment of vaccine critic Robert F Kennedy Jr as US health secretary spooked global pharmaceutical and biotech st...

ANGLE PLC’s Liquid Biopsy Technology Paves the Way for Breakthroughs...

Highlights:,Innovative Liquid Biopsy Advances:,ANGLE PLC presented new data on Parsortix-based assays for lung and breast cancer diagnostics, highligh...

Pharma Stocks Sink as Trump's Health Secretary Appointment Sparks Ma...

Highlights:,Market Reaction,:,GSK and AstraZeneca lost,nearly £7 billion,in combined market value following the appointment of Robert F Kennedy Jr., a...

PDS Biotech Streamlines Clinical Trials Amid Positive Pipeline Devel...

Highlights:,Optimized Phase 3 Trial Design,: PDS Biotech revises VERSATILE-003 trial for cost and timeline efficiency, seeking FDA clearance.,Promisin...

AstraZeneca Raises Full-Year Forecast as Oncology Portfolio Drives S...

Highlights:,Upgraded Sales and Earnings Forecast:,AstraZeneca raised its 2024 guidance for both sales and earnings for the second time in four months,...

AstraZeneca Faces Uncertainty Amid Chinese Criminal Probe as Busines...

Highlights:,AstraZeneca under Investigation:,Chinese authorities have detained AstraZeneca's top executives, including its China president, over alleg...

AstraZeneca Boosts 2024 Sales Forecast, Unveils $3.5 Billion U.S. Ex...

Highlights,AstraZeneca raises full-year sales outlook, forecasting high-teens percentage growth.,Plans $3.5 billion U.S. investment by 2026, creating...

ConvaTec Raises Full-Year Outlook as Strong Revenue Growth Boosts Co...

Highlights:,●,Upgraded Guidance:,ConvaTec raises its full-year organic revenue growth forecast to 7.25-8.0% from 5-7%.,●,Improved Profit Margin:,Adjus...

23andMe Cuts 40% of Staff, Exits Therapeutics Amid Financial Strain

Highlights:,Workforce and Strategy Overhaul,: 23andMe cuts 40% of staff and halts therapeutics programs to focus on core genetics business, targeting...

Could Polarean Imaging’s New VP Truly Drive Growth in Lung Imaging?

Highlights,Polarean Imaging focuses on advancements in functional lung imaging technology.,The company has set a higher revenue target, emphasizing gr...

AstraZeneca Unveils Ambitious $3.5 Billion Expansion Plan in the U.S...

Highlights:,Major U.S. Investment:,AstraZeneca to invest $3.5 billion in expanding its R&D and manufacturing capabilities across the U.S. by 2026.,Job...

GSK Downgraded as Analysts Cite Limited Near-Term Growth Prospects

Highlights:,Jefferies Downgrades GSK:,US bank Jefferies has reduced GSK's rating to 'hold,' citing a lack of upcoming catalysts for growth.,Concerns O...